BCMLT
LCTX icon

Beacon Capital Management LLC (Tennessee)’s Lineage Cell Therapeutics LCTX Stock Holding History

Beacon Capital Management LLC (Tennessee)’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,000
Closed -$25.4K – 161
2025
Q3 		$25.4K Hold
15,000
– – ﹤0.01% 139
2025
Q2 		$13.6K Hold
15,000
– – ﹤0.01% 568
2025
Q1 		$6.77K Hold
15,000
– – ﹤0.01% 703
2024
Q4 		$7.54K Hold
15,000
– – ﹤0.01% 648
2024
Q3 		$13.6K Hold
15,000
– – ﹤0.01% 578
2024
Q2 		$15K Hold
15,000
– – ﹤0.01% 496
2024
Q1 		$22.2K Hold
15,000
– – ﹤0.01% 433
2023
Q4 		$17.7K Buy
+15,000
New +$16.4K 0.01% 408

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Beacon Capital Management LLC (Tennessee)'s LCTX Position: Q4 2025 in Review

Beacon Capital Management LLC (Tennessee) sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 15,000 shares — an estimated $25.4K sold.

Beacon Capital Management LLC (Tennessee) first reported a position in LCTX in Q4 2023 and held it in 8 quarters. The position peaked at $25.4K in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • Beacon Capital Management LLC (Tennessee) reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Beacon Capital Management LLC (Tennessee) sold 15,000 Lineage Cell Therapeutics shares in Q4 2025, an estimated $25.4K.
  • Beacon Capital Management LLC (Tennessee) first reported a position in Lineage Cell Therapeutics in Q4 2023 and held it in 8 quarters.
  • Beacon Capital Management LLC (Tennessee)'s Lineage Cell Therapeutics position peaked at $25.4K in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on Beacon Capital Management LLC (Tennessee)'s 13F filing for Q4 2025, filed 13 Feb 2026.